BioCardia Files S-1 Registration Statement

TL;DR

BioCardia just filed an S-1, looks like they're raising capital.

AI Summary

BioCardia, Inc. filed an S-1 registration statement with the SEC on August 9, 2024, to register securities under the Securities Act of 1933. The company, formerly known as Tiger X Medical, Inc., is based in Sunnyvale, California, and operates in the biological products sector. Peter Altman is listed as a contact person.

Why It Matters

This S-1 filing indicates BioCardia, Inc. is preparing to offer new securities to the public, which could impact its capital structure and future growth prospects.

Risk Assessment

Risk Level: medium — S-1 filings are standard for companies planning to issue securities, but the specific details of the offering and the company's financial health will determine the actual risk.

Key Numbers

• 333-281448 — SEC File Number (Identifies this specific SEC filing)
• 23-2753988 — IRS Employer Identification Number (Company's tax identification number)

Key Players & Entities

• BioCardia, Inc. (company) — Registrant
• August 9, 2024 (date) — Filing Date
• Securities Act of 1933 (legal_document) — Governing Act
• Tiger X Medical, Inc. (company) — Former Company Name
• Sunnyvale, California (location) — Principal Executive Offices
• Peter Altman (person) — Contact Person

FAQ

Key Financial Figures

• $0.001 — o shares of our common stock, par value $0.001 per share ("Common Stock"), together wi
• $50,000 — ffering in an aggregate amount of up to $50,000, and (ii) non-accountable expenses paya
• $10,000 — payable to the Placement Agent of up to $10,000. See "Plan of Distribution" for a compl
• $250 million — on Stock held by non-affiliates exceeds $250 million as of the prior June 30 or (ii) our ann
• $100 million — 30 or (ii) our annual revenue exceeded $100 million during such completed fiscal year and t
• $700 million — on Stock held by non-affiliates exceeds $700 million as of the prior June 30. Corporate Inf
• $0 — d to the public in this offering, minus $0.001, and the exercise price of each Pre

Filing Documents

• bcda20240808_s1.htm (S-1) — 425KB
• ex_711385.htm (EX-3.1) — 41KB
• ex_711393.htm (EX-4.4) — 120KB
• ex_711394.htm (EX-10.10) — 17KB
• ex_711395.htm (EX-10.11) — 21KB
• ex_711422.htm (EX-23.1) — 3KB
• ex_711396.htm (EX-FILING FEES) — 25KB
• bcda20240808_s1img001.jpg (GRAPHIC) — 4KB
• bcda20240808_s1img002.jpg (GRAPHIC) — 4KB
• 0001437749-24-025899.txt ( ) — 881KB
• bcda-20240809.xsd (EX-101.SCH) — 3KB
• bcda-20240809_def.xml (EX-101.DEF) — 8KB
• bcda-20240809_lab.xml (EX-101.LAB) — 10KB
• bcda-20240809_pre.xml (EX-101.PRE) — 8KB
• bcda20240808_s1_htm.xml (XML) — 2KB

RISK FACTORS

RISK FACTORS 5 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS 9 MARKET, INDUSTRY AND OTHER DATA 10

USE OF PROCEEDS

USE OF PROCEEDS 11 DIVIDEND POLICY 12 CAPITALIZATION 13

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 15 MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF OUR COMMON STOCK, PRE-FUNDED WARRANTS AND COMMON WARRANTS 18 PLAN OF DISTRIBUTION 25 LEGAL MATTERS 26 EXPERTS 26 WHERE YOU CAN FIND MORE INFORMATION 26 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 26 Neither we nor the Placement Agent have authorized anyone to provide any information or to make any representations other than those contained or incorporated by reference in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained or incorporated by reference in this prospectus is accurate only as of its date regardless of the time of delivery of this prospectus or of any sale of securities. For investors outside the United States, neither we nor the Placement Agent have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required. Persons outside the United States who come into possession of this prospectus and any free writing prospectus related to this offering are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus and any such free writing prospectus applicable to that jurisdiction. -i- PROSPECTUS SUMMARY This summary highlights certain information about us and this offering. Because it is a summary, it does not contain all of the information that you should consider before investing. Before investing in our securities, you should read this entire prospectus and the documents incorporated by reference

View Full Filing

View this S-1 filing on SEC EDGAR